These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 27743568)

  • 41. Ultrasound of the liver.
    Kono Y; Mattrey RF
    Radiol Clin North Am; 2005 Sep; 43(5):815-26, vii. PubMed ID: 16098341
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Gaucher disease in the liver on hepatocyte specific contrast agent enhanced MR imaging.
    Ayyala RS; Teot LA; Perez Rossello JM
    Pediatr Radiol; 2017 Apr; 47(4):484-487. PubMed ID: 28144704
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Practical use and pitfalls of hepatocyte-specific contrast agents (HSCAs) for pediatric hepatic and biliary magnetic resonance imaging.
    Ayyala RS; Anupindi SA; Callahan MJ
    Abdom Radiol (NY); 2017 Feb; 42(2):502-520. PubMed ID: 27680015
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Association between non-hypervascular hypointense nodules on gadoxetic acid-enhanced MRI and liver stiffness or hepatocellular carcinoma.
    Hwang JA; Kang TW; Kim YK; Kim SH; Paik YH; Ha SY; Kim S
    Eur J Radiol; 2017 Oct; 95():362-369. PubMed ID: 28987693
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Recent advances in non-invasive magnetic resonance imaging assessment of hepatocellular carcinoma.
    Ippolito D; Inchingolo R; Grazioli L; Drago SG; Nardella M; Gatti M; Faletti R
    World J Gastroenterol; 2018 Jun; 24(23):2413-2426. PubMed ID: 29930464
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Imaging of focal liver lesions.
    Jang HJ; Yu H; Kim TK
    Semin Roentgenol; 2009 Oct; 44(4):266-82. PubMed ID: 19715792
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mangafodipir trisodium (MnDPDP)-enhanced magnetic resonance imaging of the liver and pancreas.
    Wang C
    Acta Radiol Suppl; 1998; 415():1-31. PubMed ID: 9571956
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Contrast enhanced ultrasound (CEUS) characterization of grey-scale sonographic indeterminate focal liver lesions in pediatric practice.
    Jacob J; Deganello A; Sellars ME; Hadzic N; Sidhu PS
    Ultraschall Med; 2013 Dec; 34(6):529-40. PubMed ID: 24132647
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Magnetic resonance imaging of the liver.
    Vassiliades VC; Bernardino ME
    Top Magn Reson Imaging; 1990 Jun; 2(3):1-16. PubMed ID: 2161245
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Liver-specific magnetic resonance contrast medium in the evaluation of chronic liver disease.
    Reis MA; Baroni RH
    Einstein (Sao Paulo); 2015; 13(2):326-9. PubMed ID: 26154554
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fast volumetric data acquisition in abdominal computed tomography and magnetic resonance imaging.
    Van Hoe L
    J Belge Radiol; 1997 Oct; 80(5):258. PubMed ID: 9400062
    [No Abstract]   [Full Text] [Related]  

  • 52. The appropriate allocation of CEUS in the diagnostic algorithm of liver lesions: a debated issue.
    Bolondi L
    Ultraschall Med; 2013 Feb; 34(1):8-10. PubMed ID: 23335229
    [No Abstract]   [Full Text] [Related]  

  • 53. CT Scan and MRI in the Differentiation of Liver Tumors.
    Hori M; Murakami T; Kim T; Tomoda K; Nakamura H
    Dig Dis; 2004; 22(1):39-55. PubMed ID: 15292694
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Focal liver lesions: role of contrast-enhanced ultrasound.
    Rettenbacher T
    Eur J Radiol; 2007 Nov; 64(2):173-82. PubMed ID: 17900841
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Diagnostic accuracy of CEUS in the differential diagnosis of small (≤ 20  mm) and subcentimetric (≤ 10  mm) focal liver lesions in comparison with histology. Results of the DEGUM multicenter trial.
    Strobel D; Bernatik T; Blank W; Schuler A; Greis C; Dietrich CF; Seitz K
    Ultraschall Med; 2011 Dec; 32(6):593-7. PubMed ID: 22161556
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [The characterization value of feridex-enhanced MR imaging for focal hepatic lesions in reference to their histological pathology].
    Yang HF; Zhou XP; Yu JQ; Song B; Guang YS; Zhang HY; Chen X
    Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):548-50. PubMed ID: 16042902
    [No Abstract]   [Full Text] [Related]  

  • 57. [Optimized detection and characterization of liver metastases : The role of current MRI contrast agents].
    Weinrich JM; Well L; Bannas P
    Radiologe; 2017 May; 57(5):373-381. PubMed ID: 28204853
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cirrhosis and pre-neoplastic lesions.
    Grazioli L; Olivetti L; Orlando E
    Abdom Imaging; 2012 Apr; 37(2):188-214. PubMed ID: 22297506
    [No Abstract]   [Full Text] [Related]  

  • 59. Imaging after local tumor therapies: kidney and liver.
    Kielar AZ; Hibbert RM; Maturen KE
    Semin Roentgenol; 2013 Jul; 48(3):273-84. PubMed ID: 23796378
    [No Abstract]   [Full Text] [Related]  

  • 60. Magnetic resonance contrast agents for liver imaging.
    Bashir MR
    Magn Reson Imaging Clin N Am; 2014 Aug; 22(3):283-93. PubMed ID: 25086930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.